Lv2
166 积分 2023-09-18 加入
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
1个月前
已完结
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
1个月前
已完结
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
1个月前
已完结
A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis
1个月前
已完结
Psoriasis
1个月前
已完结
Psoriasis
1个月前
已完结
Psoriasis
1个月前
已完结
Reframing Immune-Mediated Inflammatory Diseases
1个月前
已关闭
Reframing Immune-Mediated Inflammatory Diseases
1个月前
已完结
Rapid remission of SAPHO syndrome with secukinumab
2个月前
已完结
皖公网安备34019202002308
